Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. – SUPN
NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction, shareholders of Supernus will receive 1.5401 common shares of Indivior for each share of Supernus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at (833) 538-3612, or visit https://www.ksfcounsel.com/cases/nasdaqgm-supn/ to learn more.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20260807988617/en/
KSF Managing Partner Lewis S. Kahn
[email protected]
(833) 538-3612
Kahn Swick & Foti, LLC
1100 Poydras St., Suite 960
New Orleans, LA 70163
KEYWORDS: Louisiana New York United States North America
INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal
MEDIA:
| Logo |
 |